Allogeneic hematopoietic stem cell transplantation (HSCT) is an important therapy for a variety of cancers, including leukemias, lymphomas, and myeloma. Several complications limit its use, including relapse of malignancy, graft-versus-host disease, and prolonged immune depletion caused by the conditioning required for successful transplantation — all of which can lead to increased morbidity and mortality after allo-HSCT. My laboratory studies clinically relevant problems in HSCT and aims to develop novel therapeutic strategies to improve patient outcome.
Marcel R. M. van den Brink, MD, PhD
Research FocusPhysician-scientist Marcel R. M. van den Brink studies the immunology of bone marrow transplantation with a particular focus on intestinal microbiome and strategies to enhance thymus and immune reconstitution
EducationMD, PhD, Universiteit Leiden
- Ghosh A, Smith M, James SE, Davila ML, Velardi E, Argyropoulos KV, Gunset G, Perna F, Kreines FM, Levy ER, Lieberman S, Jay HV, Tuckett AZ, Zakrzewski JL, Tan L, Young LF, Takvorian K, Dudakov JA, Janq RR, Hanash AM, Motta ACF, Murphy GF, Liu C, Schietinger A, Sadelain M, van den Brink MRM. Donor CD19 CAR T cells exert potent graft-versus lymphoma activity with diminished graft-versus-host activity. Nature Medicine. 2017. 23(2):242-249. (commentary in Nature Medicine 2017; 23(2):147-148.) PMID: 28067900; PMC5528161
- Shono Y, Docampo MD, Peled JU, Perobelli SM, Velardi E, Tsai JJ, Slingerland AE, Smith OM, Young LF, Gupta J, Lieberman SR, Jay HV, Ahr KF, Rodriguez KAP, Xu K, Calarfiore M, Poeck H, Caballero S, Devlin SM, Rapaport F, Dudakov JA, Hanash AM, Gyurkocza B, Murphy GF, Gomes CG, Liu C, Moss EL, Falconer SB, Bhatt AS, Taur Y, Pamer EG, van den Brink MRM*, Jenq RR*. (*these authors contributed equally). Increased GVHD-related mortality with broad-spectrum antibiotic use after allogeneic hematopoietic stem cell transplantation in human patients and mice. Sci Transl Med. 2016; 8(339): 339ra71. PMID: 27194729; PMC4991773